The role of adjuvants and delivery systems in modulation of immune response to vaccines

Advances in Experimental Medicine and Biology

Volumn 397, Issue , 1996, Pages 105-113

  Gupta, Rajesh K ^a   Griffin Jr , Paul ^a   Chang, An Cheng ^a   Rivera, Rachel ^a   Anderson, Roger ^a   Rost, Bradford ^a   Cecchini, Douglas ^a   Nicholson, Mary ^a   Siber, George R ^a  

^a MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBUNIT; VACCINE;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0030028907     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-1382-1_15     Document Type: Conference Paper

References (44)

1. Allison, A.C., and Byars, N.E., 1990, Adjuvants for a new generation of vaccines, in: New Generation Vaccines (G.C. Woodrow, and M.M. Levine, eds.), Marcel Dekker, New York, pp. 129-140.
2. Alonso, M.J., Gupta, R.K., Min, C., Siber, G.R., and Langer, R., 1994, Biodegradable microspheres as controlled-release tetanus toxoid delivery systems, Vaccine 12:299-306.
3. Aprile, M.A., and Wardlaw, A.C., 1966, Aluminum compounds as adjuvants for vaccine and toxoids in man: A review, Can. J. Publ. Health 57:343-354.
4. Audibert, F.M., and Lise, L.D., 1993, Adjuvants: current status, clinical perspectives and future prospects, Immunology Today 14:281-284.
5. Barington, T., Skettrup, M., Juul, L., and Heilman, C., 1993, Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components, Infect. Immun. 61:432-438.
6. Cooper, P.D., 1994, The selective induction of different immune responses by vaccine adjuvants, in: Strategies in Vaccine Design (G.L. Ada ed.), R.G. Landes Company, Austin, pp. 125-158.
7. Coutelier, J.P., van der Logt, J.T., Heessen, F.W.A., Warnier, G., and van Snick, J., 1987, IgG2a restriction of murine antibodies elicited by viral infections, J. Exp. Med. 165:64-69.
8. Dahlback, M., Bergstr, H., Pauwels, R., and Bazin, H., 1983, The non-specific enhancement of allergy III. Precipitation of bronchial anaphylactic reactivity in primed rats by injection of alum or B. pertussis vaccine: Relation of response capacity to IgE and IgG2a antibody levels, Allergy 38:261-271.
9. Eldridge, J.H., Gilley, R.M., Staats, J.K., Moldoveanu, Z., Meulbroek, J.A., and Tice, T.R., 1989, Biodegradable microspheres: vaccine delivery system for oral immunization, Curr. Topics Microbiol. Immunol. 146:59-66.
10. Eldridge, J.H., Staas, J.K., Meulbroek, J.A., Tice, T.R., and Gilley R.M., 1991, Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for Staphylococcal enterotoxin B toxoid which enhances the level of toxin- neutralizing antibodies, Infect. Immun. 59:2978-2986.
11. Ellis, R.W., and Douglas, R.G., Jr., 1994, Combination vaccines, Int. J. Technol. Assess. Hlth care 10:185-192.
12. Food and Drug Administration, 1993a, Approval of a new Haemophilus influenzae type b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus influenzae type b conjugate vaccine for infants and children, MMWR 42:296-298.
13. Food and Drug Administration, 1993b, Approval of use of Haemophilus influenzae type b conjugate vaccine reconstituted with diphtheria-tetanus-pertussis vaccine for infants and children. MMWR 42:964-966.
14. Glenny, A.T., Pope, C.G., Waddington, H., and Wallace, U., 1926, The antigenic value of toxoid precipitated by potassium alum, J. Pathol. Bacterial. 29:38-45.
15. Golding, B., 1991, Cytokine regulation of humoral immune responses, in: Topics in Vaccine Adjuvant Research (D.R. Spriggs, and W.C. Koff, eds.), CRC, Boca Raton, pp. 25-37.
16. Gupta, R.K., and Siber, G.R., 1994a, Comparison of adjuvant activities of aluminum phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid, Biologicals 22:53-63.
17. Gupta, R.K., and Siber, G.R., 1994b, Comparative analysis of tetanus antitoxin titers of sera from immunized mice and guinea pigs determined by toxin neutralization test and enzyme-linked immunosorbent assay, Biologicals 22:215-219.
18. Gupta, R.K., and Siber, G.R., 1995a, Adjuvants for human use: current status, problems and future prospects, Vaccine 13:1263-1276.
19. Gupta, R.K., and Siber, G.R., 1995b, Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay, J. Immunol. Methods 181:75-81.
20. Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S., and Gupta C.K., 1993a, Adjuvants - a balance between toxicity and adjuvanticity, Vaccine 11:293-306.
21. Gupta, R.K., Siber, G.R., Alonso, M.J., and Langer, R., 1993b, Development of a single-dose tetanus toxoid based on controlled release from biodegradable and biocompatible polyester microspheres, in: Vaccines 93 (F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 391-396.
22. Gupta, R.K., Higham, S., Gupta, C.K., Rost, B., and Siber, G.R., 1994a, Suitability of the Vero cell method for titration of diphtheria antitoxin in the United States potency test for diphtheria toxoid, Biologicals 22:65-72.
23. Gupta, R., Griffin, P., Lees, A., Mond, J., Varanelli, C., Wallach, D., Cooper, P., Alonso, M., Langer, R. and Siber, G., 1994b, Comparative evaluation of aluminum phosphate, calcium phosphate, stearyl tyrosine, γ inulin, conjugation to dextran, liposomes and poly lactide/glycolide microspheres as adjuvant delivery systems for tetanus and diphtheria toxoids. Paper presented at the 94th General Meeting of the American Society for Microbiology, May 23-27, 1994, at Las Vegas, NV. American Society for Microbiology, Washington, DC, p. 147.
24. Gupta, R.K., Siber, G.R., Lees, A. and Mond, J.J., 1994c, Conjugation of multiple copies of T-cell dependent antigens on a large molecular weight polysaccharide carrier enhances antibody response to both components. Paper presented at the Second International Conference on Vaccines: New Technologies & Applications, March 21-23, 1994, Alexandria, VA. Waltham: Cambridge Healthtech Institute.
25. Gupta, R.K., Rost, B.E., Relyveld, E., and Siber, G.R., 1995a, Adjuvant Properties of aluminum and calcium compounds, in: Vaccine Design: The Subunit Approach (M.F. Powell, and M.J. Newman, eds.), Plenum Publishing Corporation, New York, pp 229-248.
26. Gupta, R.K., Anderson, R., Cecchini, D., Rost, B., Griffin, P., Benscoter, K., Xu, J., Montanez-Ortiz, L., and Siber, G.R., 1995b, Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus, acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines, Dev. Biol. Stand. 86:281-294.
27. Gupta, R.K., Varanelli, C.L., Griffin, P., Wallach, D.F.H. and Siber, G.R., 1995c, Adjuvant properties of non-phospholipid liposomes (Novasomes®) in experimental animals for human vaccine antigens. Vaccine (in press).
28. Herzenberg, L.A., Tokuhisa, T. and Hayakawa, K, 1983, Epitope-specific regulations, Ann. Rev. Immunol. 1:609-632.
29. Kensil, C.R., Newman, M.J., Coughlin, R.T., Soltysik, S., Bedore, D., Recchia, J., Wu, J.- Y., and Marciani, D.J., 1993, The use of Stimulon adjuvant to boost vaccine response, Vacc. Res. 2:273-282.
30. Martin, S., Daniel, S.L., and Rouse, B.T., 1991, Cytokines and regulation of cellular immune responses to viruses, in: Topics in Vaccine Adjuvant Research (D.R. Spriggs, and W.C. Koff, eds.), CRC, Boca Raton, pp. 39-50.
31. Morris, W., Steinhoff, M.C., and Russell, P.K., 1994, Potential of polymer microencapsulation technology for vaccine innovation, Vaccine 12:5-11.
32. Neefjes, J.J., Schumacher, T.N.M., and Ploegh, H.L., 1991, Assembly and intracellular transport of major histocompatibility complex molecules, Curr. Opin. Cell. Biol. 3:601-609.
33. O'Hagan, D.T., Jeffery, H., and Davis, S.S., 1993, Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles, Vaccine 11:965-969.
34. Paul, W.E., 1993, The immune system, in: Fundamental Immunology (W.E. Paul, ed.) Third Edition, Raven Press, New York, pp. 1-20.
35. Ramon, G., 1925, Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphterique, Bull Soc. Centr. Med. Vet. 101:227-234.
36. Ramon, G., 1926, Procedres pour acroitre la production des antitoxines, Ann. Institut Pasteur 40:1-10.
37. Robbins, J.B., and Schneerson, R., 1990, Polysaccharide-protein conjugates: a new generation of vaccines, J. Infect. Dis. 161:821-832.
38. Salk, J., Bretscher, P.A., Salk, P.L., Clerici, M., and Shearer, G. M., 1993, A strategy for prophylactic vaccination against HIV, Science 260:1269-1271.
39. + functional T cell subsets: their roles in infection and vaccine development, in: Strategies in Vaccine Design (G.L. Ada ed.), R.G. Landes Company, Austin, pp. 113-124.
40. Siber, G.R., 1994, Pneumococcal disease: Prospects for a new generation of vaccines, Science 265:1385-1387.
41. Singh, M., Singh, O., Singh, A., and Talwar, G.P., 1992, Immunogenicity studies on diphtheria toxoid loaded biodegradable microsphcres, Int. J. Pharmaceutics 85:R5-R8.
42. Staats, H.F., Jackson, R.J., Marinaro, M., Takahashi, I., Kiyono, H., and McGhee, J.R., 1994, Mucosal immunity to infection with implications for vaccine development, Curr. Biol. 6:572-583.
43. Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N., and Berzofsky, J.A., 1990, Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMs, Nature (London) 344:873-875.
44. Wu, J.-Y., Gardner, B.H., Murphy, C.I., Seals, J.R., Kensil, C.R., Recchia, J., Beltz, G.A., Newman, G.W., and Newman, M.J., 1992, Saponin adjuvant enhancement of antigen specific immune responses to an experimental HIV-1 vaccine, J. Immunol. 148:1519-1525.